- Home
- SHMD vs ENTX Comparison
SHMD vs ENTX Comparison
Compare SHMD & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHMD | ENTX |
|---|---|---|
| Founded | 1864 | 2010 |
| Country | Germany | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.0M | 74.7M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | SHMD | ENTX |
|---|---|---|
| Price | $6.47 | $1.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 780.1K | 102.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | N/A | ★ $181,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $1.00 |
| 52 Week High | $10.65 | $3.22 |
Technical Indicators
Market Signals| Indicator | SHMD | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.76 | 42.91 |
| Support Level | $2.38 | $1.17 |
| Resistance Level | $6.70 | $2.28 |
| Average True Range (ATR) | 0.97 | 0.14 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 21.28 | 23.91 |
Price Performance
Historical ComparisonAbout SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.